Vinorelbine Chemotherapy for Soft-Tissue Sarcomas
Author Information
Author(s): Sibyl E. Anderson, Mary L. Keohan, David R. D'Adamo, Robert G. Maki
Primary Institution: Memorial Sloan-Kettering Cancer Center
Hypothesis
The role of vinorelbine in specific soft tissue sarcoma subtypes is unclear.
Conclusion
Vinorelbine demonstrates limited activity in a heavily pretreated group of soft-tissue sarcoma patients.
Supporting Evidence
- The overall response rate to vinorelbine was 6%, with 3 patients showing partial responses.
- 14 patients (26%) experienced stable disease as their best response.
- The median time to progression was 1.8 months.
Takeaway
This study looked at how well vinorelbine works for patients with a type of cancer called soft-tissue sarcoma. It found that it doesn't work very well for most patients who have already had a lot of other treatments.
Methodology
Retrospective analysis of 58 patients treated with vinorelbine chemotherapy at a single institution.
Limitations
The study is limited by its retrospective nature and the heavily pretreated patient population.
Participant Demographics
The cohort included 26 men and 32 women with a median age of 52 years.
Statistical Information
Confidence Interval
1.5–2.1 months for time to progression; 4.1–8.7 months for overall survival.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website